


Editor

Leo van de Putte (The Netherlands)

Associate editorsThomas Bardin (France)
Johannes Bijlsma (The Netherlands)
Gerd Burmester (Germany)Bevrah Hahn (USA)
Frank Wollheim (Sweden)
Anthony Woolf (UK)**Methodological adviser**

Jaap Fransen (The Netherlands)

Editorial boardM Aringer (Austria)
P Bacon (UK)
F Berenbaum (France)
M Boers (The Netherlands)
D Boumpas (Greece)
B Bresnihan (Ireland)
H Capell (UK)
M Cutolo (Italy)
G Firestein (USA)
P Goupille (France)
E Gravallese (USA)
W Gross (Germany)
F Guillemain (France)
G Herrero-Beaumont (Spain)
F Houssiau (Belgium)
T Huizinga (The Netherlands)
C Jorgensen (France)
G Kollias (Greece)
T Kvien (Norway)
M Leirisalo-Repo (Finland)
F Luijten (Belgium)
H-M Lorenz (Germany)
W Maslinski (Poland)
M Matucci Cerinic (Italy)K Nishioka (Japan)
M Nurmohamed
(The Netherlands)
S Özen (Turkey)
T Pap (Germany)
E Pascual Gómez (Spain)
L Punzi (Italy)
L Rönnblom (Sweden)
B Rozman (Slovenia)
G Schett (Austria)
J Da Silva (Portugal)
H Schulze-Koops (Germany)
A So (Switzerland)
T Sokka (USA)
D Symmons (UK)
P-P Tak (The Netherlands)
A Tyndall (Switzerland)
A Tzioufas (Greece)
J Vencovsky (Czech Republic)
M Ward (USA)
M Weisman (USA)
H Yazici (Turkey)
Editor, *BMJ***Advisory committee**W vd Berg (The Netherlands)
S Bombardieri (Italy)
F Breedveld (The Netherlands)
L Crofford (USA)
J-M Dayer (Switzerland)
M Doherty (UK)
M Dougados (France)
J Edmonds (Australia)
P Emery (UK)
D Furst (USA)
S Gay (Switzerland)
J Kalden (Germany)
E Keystone (Canada)
L Klarenskog (Sweden)P Lipsky (USA)
S Lohmander (Finland)
R Maini (UK)
E M Mola (Spain)
H Moutsopoulos (Greece)
J O'Dell (USA)
K Pavelka (Czech Republic)
J Rovinsky (Slovakia)
Y Shoenfeld (Israel)
J Smolen (Austria)
W van Venrooy
(The Netherlands)
E Veys (Belgium)
A Wiik (Denmark)**Guidelines for authors and reviewers**Guidance for authors and reviewers can be found at <http://ard.bmj.com/ffora>
All papers must be submitted via Bench>Press at www.submit-ard.bmj.com**Disclaimer***Annals of the Rheumatic Diseases* is published by BMJ Publishing Group Ltd, a wholly owned subsidiary of the British Medical Association, and the European League Against Rheumatism.The BMA grants editorial freedom to the Editor of the *Annals of the Rheumatic Diseases*. The *Annals of the Rheumatic Diseases* follows guidelines on editorial independence produced by the World Association of Medical Editors and the code on good publication practice of the Committee on Publication Ethics.The *Annals of the Rheumatic Diseases* is intended for medical professionals and is provided without warranty, express or implied. Statements in the journal are the responsibility of their authors and advertisers and not authors' institutions, the BMJ Publishing Group, The European League Against Rheumatism or the BMA unless otherwise specified or determined by law. Acceptance of advertising does not imply endorsement. To the fullest extent permitted by law, the BMJ Publishing Group shall not be liable for any loss, injury or damage resulting from the use of the *Annals of the Rheumatic Diseases* or any information in it whether based on contract, tort, or otherwise. Readers are advised to verify any information they choose to rely on.**Subscription information**See p iv
ISSN 0003-4967 (print); 1468-2060 (online)**Copyright**© 2007 BMJ Publishing Group and European League Against Rheumatism. All rights reserved; no part of this publication may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, recording, or otherwise without the prior permission of *Annals of the Rheumatic Diseases*Authors are required to grant *Annals of the Rheumatic Diseases* an exclusive licence to publish; further details available online at <http://annrheumdis.com/ffora/licence.dtl>• *Annals of the Rheumatic Diseases* is published by BMJ Publishing Group, copyedited by Macmillan India Ltd, typeset by The Charlesworth Group, and printed in the UK on acid-free paper by Cambrian Printers Limited, Aberystwyth• Periodicals postage paid, Rahway, NJ. Postmaster: send address changes to: *Annals of the Rheumatic Diseases*, c/o Mercury Airfreight International Ltd, 365 Blair Road, Avenel, NJ 07001, USA

Cytokine, chemokine and soluble adhesion molecule profiles in plasma and synovial fluid of patients with juvenile idiopathic arthritis. See p 589.

www.publicationethics.org.uk

This journal is a member of and subscribes to the principles of the Committee on Publication Ethics

Editorial

- 569 Why we need guidelines for clinical trials in vasculitis and systemic lupus erythematosus
C Mukhtyar, D Boumpas, C Gordon, W Gross, D Jayne, R Luqmani

Review

- 571 Cognitive-behavioural therapies and exercise programmes for patients with fibromyalgia: state of the art and future directions
S van Koulil, M Effting, F W Kraaijaat, W van Lankveld, T van Helmond, H Cats, P L C M van Riel, A J L de Jong, J F Haverman, A W M Evers

Extended reports

- 582 Therapeutic effect of cortistatin on experimental arthritis by downregulating inflammatory and Th1 responses
E Gonzalez-Rey, A Chorny, R G Del Moral, N Varela, M Delgado
- 589 Blood and synovial fluid cytokine signatures in patients with juvenile idiopathic arthritis: a cross-sectional study
W de Jager, E P A H Hoppenreijs, N M Wulffraat, L R Wedderburn, W Kuis, B J Prakken
- 599 T cell responses to a non-glycosylated epitope predominate in type II collagen-immunised HLA-DRB1*0101 transgenic mice
A von Delwig, D M Altmann, F G Charlton, N McKie, J D Isaacs, R Holmdahl, J H Robinson
- 605 EULAR recommendations for conducting clinical studies and/or clinical trials in systemic vasculitis: focus on anti-neutrophil cytoplasmic antibody-associated vasculitis
B Hellmich, O Flossmann, W L Gross, P Bacon, J W Cohen-Tervaert, L Guillevin, D Jayne, A Mahr, P A Merkel, H Raspe, D G I Scott, J Witter, H Yazici, R A Luqmani, on behalf of the European Vasculitis Study Group
- 618 African-American and Hispanic ethnicities, renal involvement and obesity predispose to hypertension in systemic lupus erythematosus: results from LUMINA, a multiethnic cohort (LUMINAXLV)
S Chaiamnuay, A M Bertoli, J M Roseman, G McGwin, M Apte, S Durán, L M Vilá, J D Reveille, G S Alarcón
- 623 Genomewide linkage scan of hand osteoarthritis in female twin pairs showing replication of quantitative trait loci on chromosomes 2 and 19
G Livshits, B S Kato, G Zhai, D J Hart, D Hunter, A J MacGregor, F M K Williams, T D Spector
- 628 Clinical trial of a leucotriene B4 receptor antagonist, BLI 284, in patients with rheumatoid arthritis
F Díaz-González, R H E Alten, W G Bensen, J P Brown, J T Sibley, M Dougados, S Bombardieri, P Durez, P Ortiz, G de-Miquel, A Staab, R Sigmund, L Salin, C Leledy, S H Polmar on behalf of the BLI 284 Rheumatoid Arthritis Collaborative Study group

- 633 Are there gender differences in severity of ankylosing spondylitis? Results from the PSOAS cohort *W Lee, J D Reveille, J C Davis Jr, T J Learch, M M Ward, M H Weisman*
- 639 Effect of chondroitin sulphate in symptomatic knee osteoarthritis: a multicentre, randomised, double-blind, placebo-controlled study *B Mazières, M Hucher, M Zaim, P Garnero*
- 646 Arthritis of the large joints—in particular, the knee—at first presentation is predictive for a high level of radiological destruction of the small joints in rheumatoid arthritis *S P Linn-Rasker, A H M van der Helm-van Mil, F C Breedveld, T W J Huizinga*
- 651 Reporting of radiographic methods in randomised controlled trials assessing structural outcomes in rheumatoid arthritis *G Baron, I Boutron, B Giraudeau, P Ravaut*
- 658 Is shared care with annual hospital review better value for money than predominantly hospital-based care in patients with established stable rheumatoid arthritis? *L M Davies, E A Fargher, K Tricker, P Dawes, D L Scott, D Symmons*
- 664 Persistence of interleukin 7 activity and levels on tumour necrosis factor α blockade in patients with rheumatoid arthritis *J A G van Roon, S A Y Hartgring, M Wenting-van Wijk, K M G Jacobs, P-P Tak, J W J Bijlsma, F P J G Lafeber*
- 670 Treatment with TNF blockers and mortality risk in patients with rheumatoid arthritis *L T H Jacobsson, C Turesson, J-Å Nilsson, I F Petersson, E Lindqvist, T Saxne, P Geborek*
- 676 Chimeric antibodies to proteinase 3 of IgG1 and IgG3 subclasses induce different magnitudes of functional responses in neutrophils *R Colman, A Hussain, M Goodall, S P Young, T Pankhurst, X Lu, R Jefferis, C O S Savage, J M Williams*
- 690 Response to intramuscular methyl prednisolone in inflammatory hand pain: evidence for a targeted clinical, ultrasonographic and therapeutic approach *Z Karim, M A Quinn, R J Wakefield, A K Brown, M J Green, E M A Hensor, P G Conaghan, P Emery*
- 693 A prospective study of anti-chromatin and anti-C1q autoantibodies in patients with proliferative lupus nephritis treated with cyclophosphamide pulses or azathioprine/methylprednisolone *C Grootsholten, J W C Dieker, F D McGrath, A Roos, R H W M Derksen, J van der Vlag, M R Daha, J H M Berden, on behalf of the Dutch Working Party on SLE*
- 697 The public neglect of rheumatic diseases: insights from analyses of attendees in a musculoskeletal disease awareness activity *K P Machold, M D Köller, S Pflugbeil, C Zimmermann, E Wagner, U Stuby, D Aletaha, T A Stamm, F Mayrhofer, A Dunky, J Hermann, W Ilias, J S Smolen, the Rheuma-Bus group of physicians*
- 700 Increase of B cell-activating factor of the TNF family (BAFF) after rituximab treatment: insights into a new regulating system of BAFF production *F Lavie, C Miceli-Richard, M Ittah, J Sellam, J-E Gottenberg, X Mariette*

Letters

- 704 Effectiveness of a once weekly double dose of etanercept in patients with juvenile idiopathic arthritis: a clinical study *F H M Prince, M Twilt, N C J A Jansen-Wijngaarden, L W A van Suijlekom-Smit*
- 706 Extrapituitary prolactin promoter polymorphism in Czech patients with systemic lupus erythematosus and rheumatoid arthritis *M Fojtíková, M Černá, P Čejková, Š Růžicková, C Dostál*
- 707 Doppler ultrasonographic characteristics of superficial and deep-flow signals in the knee joint pannus of patients with rheumatoid arthritis *R Kasukawa, K Shio, Y Kanno, A Sato, A Takahashi, Y Yamadera, T Kanno*

Concise reports

- 683 Investigation of genetic variation across the protein tyrosine phosphatase gene in patients with rheumatoid arthritis in the UK *A Hinks, S Eyre, A Barton, W Thomson, J Worthington*
- 687 A randomised, double-blind, placebo-controlled trial of a recombinant version of human α -fetoprotein (MM-093) in patients

- 708 Forthcoming events
- 708 Correction